Comprehensive cancer somatic panel

Comprehensive cancer somatic panel

Tumor molecular profile analysis by Next Generation Sequencing technology is currently widely applied in clinical practice and has enabled the detection of predictive biomarkers of response to targeted treatment. In parallel with targeted therapies, immunotherapies are also evolving, revolutionizing cancer therapy, with Programmed Death-ligand 1 (PD-L1), Microsatellite instability (MSI), and Tumor Mutational Burden (TMB) analysis being the biomarkers employed most commonly.

The complete genomic profiling is the “Concurrent Gene agnosTic tissue and liquid testing” is the most comprehensive cancer profiling which combine tissue biopsy testing and liquid biopsy testing, seek for the best possible solution of individual patient.

Gene agnosTic tissue testing provides a comprehensive genomic profile for the individual cancer patient, combined with the immunotherapy biomarker TMB, MSI, and the biomarkers for homologous recombination status (LOH, TSI, LAT).

Gene agnosTic tissue plus hereditary cancer normal matched testing composed of tissue testing plus PDL-1, and germline variants for normal-tumor matching.

Our comprehensive Cancer Panel (tissue testing) profile 500+ unique genes for single gene and multi-gene biomarker insights, enables analysis of various single-gene variants, such as SNVs, indels, fusions, splice variants, and CNV, including both copy number gains and losses across 500+ genes, detection of complex biomarkers associated with immunotherapies such as TMB, MSI, support Homologous Recombination Deficiency (HRD) research by detecting mutations in 46 HRR genes, including BRCA LGRs, and assessment genomic scarring with the genomic instability metric (GIM) and enables more samples are successfully tested due to low QNS readings and high sequencing success rates of >95%. Each and every gene is carefully selected by the oncology informatics team based on proprietary databases, peer-reviewed literature, and competitive/industry data, and confirmed with industry-leading pharmaceutical partners.

Analyze multiple biomarkers simultaneously

Detect and analyze all single and multiple gene biomarkers simultaneously from just 20 ng of DNA and RNA from FFPE samples.

Single gene biomarkers

Detect all types of single-gene variants for targeted-therapy research, such as single-nucleotide variants (SNVs), indels, fusions, splice variants, MET exon skipping at DNA and RNA level and copy number variants (CNVs), including both CNV gain and CNV loss.
Multi-gene biomarkers

Detect emerging biomarkers such as TMB for study of potential response to immunotherapies and MSI for study of predisposition to genetic hypermutability. Analyze mutational signatures, including homologous recombination deficiency (HRD) status through detection of the consequences of genomic instability using GIM.

Robust fusion detection

With FusionSync technology, tissue testing panels covers >1300 isoforms with 49 fusion drivers, and enables: fusion detection from low input samples, detection of low level of fusion transcripts and ability to detect novel fusions for driver genes

Homologous recombination deficiency

Homologous recombination deficiency (HRD) is becoming a hot biomarker in precision oncology clinical research. Under normal conditions, errors during homologous recombination are repaired in the HRR pathway. Errors in the HRR pathway, such as loss-of-function or deleterious mutations in the associated genes, lead to higher levels of genomic instability. Tissue testing covers 46 key genes in the HRR pathway and measures genomic instability using GIM.

For Research Use Only. Not for any animal or human therapeutic or diagnostic use.
https://www.thermofisher.com/th/en/home/clinical/preclinical-companion-diagnostic-development/oncomine-oncology/oncomine-cancer-research-panel-workflow/oncomine-comprehensive-assay-plus.html

Utility of the comprehensive cancer profiling tests

Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion

“Patients with metastatic or advanced cancer should undergo genomic sequencing in a certified laboratory if the presence of one or more specific genomic alterations has regulatory approval as biomarkers to guide the use of or exclusion from certain treatments for their disease. Multigene panel–based assays should be used if more than one biomarker-linked therapy is approved for the patient's disease. Site-agnostic approvals for any cancer with a high tumor mutation burden, mismatch repair deficiency, or neurotrophic tyrosine receptor kinase (NTRK) fusions provide a rationale for genomic testing for all solid tumors. Multigene testing may also assist in treatment selection by identifying additional targets when there are few or no genotype-based therapy approvals for the patient's disease. For treatment planning, the clinician should consider the functional impact of the targeted alteration and expected efficacy of genomic biomarker–linked options relative to other approved or investigational treatments.”

DOI: 10.1200/JCO.21.02767 Journal of Clinical Oncology 40, no. 11 (April 10, 2022) 1231-1258.